المؤلفون: Cioffi R, Bergamini A, Gadducci A, Cormio G, Giorgione V, Petrone M, Rabaiotti E, Pella F, Candiani M, Mangili G

المصدر: International journal of gynecological cancer : official journal of the International Gynecological Cancer Society [Int J Gynecol Cancer] 2018 Feb; Vol. 28 (2), pp. 332-337.

نوع المنشور: Comparative Study; Journal Article

بيانات الدورية: Publisher: BMJ Country of Publication: England NLM ID: 9111626 Publication Model: Print Cited Medium: Internet ISSN: 1525-1438 (Electronic) Linking ISSN: 1048891X NLM ISO Abbreviation: Int J Gynecol Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents/*administration & dosage , Gestational Trophoblastic Disease/*drug therapy , Gestational Trophoblastic Disease/*epidemiology , Pregnancy Outcome/*epidemiology, Adult ; Antineoplastic Combined Chemotherapy Protocols/administration & dosage ; Chemotherapy, Adjuvant/statistics & numerical data ; Clinical Trials as Topic/statistics & numerical data ; Combined Modality Therapy ; Cyclophosphamide/administration & dosage ; Dactinomycin/administration & dosage ; Etoposide/administration & dosage ; Female ; Humans ; Hysterectomy/statistics & numerical data ; Infant, Newborn ; Italy/epidemiology ; Male ; Methotrexate/administration & dosage ; Multicenter Studies as Topic/statistics & numerical data ; Pregnancy ; Retrospective Studies ; Vincristine/administration & dosage ; Young Adult

SCR Protocol: EMA-CO protocol

المؤلفون: Gridelli C; Division of Medical Oncology, 'S. G. Moscati' Hospital, Avellino, Italy., Ascierto PA; Unit of Melanoma, Cancer Immunotherapy and Development Therapeutics Istituto Nazionale Tumori Fondazione G. Pascale, Napoli, Italy., Grossi F; Lung Cancer Unit, IRCCS AOU San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, L.go R. Benzi 10, 16132 Genova, Italy., Baldini E; Department of Medical Oncology, Medical Oncology Div. S. Luca Hospital, Lucca, Italy., Favaretto A; Departement of Medical Oncology, Ospedale Ca` Foncello, AULSS 2, Marca Trevigiana, Treviso, Italy., Garassino MC; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan, Italy., Morabito A; Thoracic Medical Oncology, Istituto Nazionale Tumori, Fondazione G. Pascale - IRCCS, Napoli, Italy., Migliorino MR; Pulmonary Oncology Unit, San Camillo-Forlanini Hospital, Rome, Italy., Rossi A; Division of Medical Oncology, IRCCS Casa Sollievo della Sofferenza Hospital, San Giovanni Rotondo (FG), Italy., de Marinis F; Thoracic Division, Medical Oncology Department, European Institute of Oncology, Milan, Italy.

المصدر: Current clinical pharmacology [Curr Clin Pharmacol] 2018; Vol. 13 (2), pp. 76-84.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Bentham Science Publishers Ltd Country of Publication: United Arab Emirates NLM ID: 101273158 Publication Model: Print Cited Medium: Internet ISSN: 2212-3938 (Electronic) Linking ISSN: 15748847 NLM ISO Abbreviation: Curr Clin Pharmacol Subsets: MEDLINE

مواضيع طبية MeSH: Algorithms* , Oncogene Addiction*/genetics, Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Carcinoma, Non-Small-Cell Lung/*drug therapy , Immunotherapy/*trends , Lung Neoplasms/*drug therapy, Angiogenesis Inhibitors/administration & dosage ; Antineoplastic Agents/administration & dosage ; Carcinoma, Non-Small-Cell Lung/epidemiology ; Carcinoma, Non-Small-Cell Lung/genetics ; Congresses as Topic/trends ; Female ; Humans ; Immunotherapy/methods ; Italy/epidemiology ; Lung Neoplasms/epidemiology ; Lung Neoplasms/genetics ; Male ; Treatment Outcome

المؤلفون: Pedrazzoli P; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy., Martinelli G; Medical Oncology, European Institute of Oncology, Milan, Italy., Gianni AM; Medical Oncology, IRCCS Foundation, National Cancer Institute, Milan, Italy., Da Prada GA; Medical Oncology, IRCCS Maugeri Foundation, Pavia, Italy., Ballestrero A; Department of Internal Medicine, University Hospital, Genova, Italy., Rosti G; Medical Oncology, Civil Hospital, Ravenna, Italy., Frassineti GL; Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy., Aieta M; Medical Oncology, IRCCS Casa Sollievo della Sofferenza, San Giovanni Rotondo (FG), Italy., Secondino S; Medical Oncology, Niguarda Ca', Granda Hospital, Milan, Italy., Cinieri S; Medical Oncology, European Institute of Oncology, Milan, Italy., Fedele R; Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera 'BMM', Reggio Calabria, Italy., Bengala C; Medical Oncology, University Hospital, Pisa, Italy., Bregni M; Hematology Unit, San Raffaele Scientific Institute, Milan, Italy., Grasso D; Medical Oncology, IRCCS Foundation, San Matteo Hospital, Pavia, Italy., De Giorgi U; Department of Medical Oncology, IRCCS Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori, Meldola, Italy., Lanza F; Section of Hematology and Bone Marrow Transplant Unit, Cremona, Italy., Castagna L; Hematology Unit, Humanitas Cancer Center, Rozzano, Milan, Italy., Bruno B; National Registry GITMO & Data Managing, Ospedale San Martino, Genova, Italy., Martino M; Hematology and Bone Marrow Transplant Unit, Azienda Ospedaliera 'BMM', Reggio Calabria, Italy. Electronic address: dr.massimomartino@gmail.com.

مؤلفون مشاركون: of Gruppo Italiano per il Trapianto di Midollo Osseo, Cellule staminali emopoietiche e terapia cellulare (GITMO) – Sezione Tumori Solidi

المصدر: Biology of blood and marrow transplantation : journal of the American Society for Blood and Marrow Transplantation [Biol Blood Marrow Transplant] 2014 Apr; Vol. 20 (4), pp. 501-6. Date of Electronic Publication: 2013 Dec 27.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Carden Jennings Publishing Country of Publication: United States NLM ID: 9600628 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1523-6536 (Electronic) Linking ISSN: 10838791 NLM ISO Abbreviation: Biol Blood Marrow Transplant Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols* , Peripheral Blood Stem Cell Transplantation* , Registries*, Breast Neoplasms/*therapy, Adult ; Aged ; Antineoplastic Agents, Alkylating/administration & dosage ; Breast Neoplasms/immunology ; Breast Neoplasms/mortality ; Breast Neoplasms/pathology ; Drug Administration Schedule ; Epirubicin/administration & dosage ; Female ; Gene Expression ; Humans ; Italy ; Lymphatic Metastasis ; Middle Aged ; Mitoxantrone/administration & dosage ; Receptor, ErbB-2/genetics ; Receptor, ErbB-2/immunology ; Risk ; Survival Analysis ; Transplantation, Autologous

المؤلفون: Casali PG; Fondazione IRCCS Istituto Nazionale Tumori, and University of Milan, Milano, Italy; Gustave Roussy, Villejuif, France. Electronic address: paolo.casali@istitutotumori.mi.it., Le Cesne A; Instituto Valenciano De Oncologia, Valencia, Spain., Velasco AP; Adelaide Cancer Centre, Kurralta Park, and Division of Medicine, University of Adelaide, Australia., Kotasek D; Maria Sklodowska-Curie Memorial Cancer Centre and Institute of Oncology, Warsaw, Poland., Rutkowski P; Mannheim University Medical Center, Mannheim, Germany., Hohenberger P; Royal Marsden Hospital, London, UK., Fumagalli E; Fondazione IRCCS Istituto Nazionale Tumori, and University of Milan, Milano, Italy; Gustave Roussy, Villejuif, France., Judson IR; Institut Bergonie, Bordeaux, France., Italiano A; Institut Bergonie, Bordeaux, France., Gelderblom H; Leiden University Medical Center, Leiden, Netherlands., Penel N; Centre Oscar Lambret, Lille, France., Hartmann JT; Medizinische Universitätsklinik II, Tübingen, Germany., Duffaud F; Hôpital de La Timone, Aix-Marseille Université, Marseille, France., Goldstein D; Prince of Wales Hospital, Sydney, Australia., Martin-Broto J; Hospital Universitari Son Espases, Palma de Mallorca, Spain., Gronchi A; Fondazione IRCCS Istituto Nazionale Tumori, and University of Milan, Milano, Italy., Wardelmann E; University Hospital Münster, Münster, Germany., Marréaud S; EORTC Headquarters, Brussels, Belgium., Zalcberg JR; School of Public Health and Preventive Medicine, Monash University, Melbourne, Australia., Litière S; EORTC Headquarters, Brussels, Belgium., Blay JY; Department of Medicine, NetSARC and LYRIC, Centre Leon Berard, Lyon, France.

المصدر: Annals of oncology : official journal of the European Society for Medical Oncology [Ann Oncol] 2021 Apr; Vol. 32 (4), pp. 533-541. Date of Electronic Publication: 2021 Jan 19.

نوع المنشور: Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 9007735 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1569-8041 (Electronic) Linking ISSN: 09237534 NLM ISO Abbreviation: Ann Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/therapeutic use , Gastrointestinal Neoplasms*/drug therapy , Gastrointestinal Stromal Tumors*/drug therapy , Sarcoma*/drug therapy, Chemotherapy, Adjuvant ; Humans ; Imatinib Mesylate/therapeutic use ; Italy ; Neoplasm Recurrence, Local/drug therapy

المؤلفون: Santini D; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome., Stellato M; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome.; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan., De Giorgi U; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola., Pantano F; Department of Medical Oncology, Campus Bio-Medico University of Rome, Rome., De Lisi D; Department of Medical Oncology, Santa Chiara Hospital, Trento., Casadei C; Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori (IRST), IRCCS, Meldola., Maruzzo M; Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS., Bimbatti D; Medical Oncology Unit 1, Department of Oncology, Istituto Oncologico Veneto IOV IRCCS., Naglieri E; Division of Medical Oncology, Istituto Tumori Bari Giovanni Paolo II-IRCCS, Bari., Buti S; Medical Oncology Unit, University Hospital of Parma, Parma., Bersanelli M; Medical Oncology Unit, University Hospital of Parma, Parma., De Vivo R; Department of Oncology, San Bortolo General Hospital, Vicenza., Di Lorenzo G; Azienda Ospedaliera Universitaria Federico II, Naples., Sbrana A; Department of Translational Research and New Technologies in Medicine and Surgery, Unit of Medical Oncology 2, Azienda Ospedaliera Universitaria Pisana, Pisa., Verzoni E; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan., Soraru' M; Oncology Unit, Camposampiero General Hospital, Camposampiero, Padua., Fornarini G; Medical Oncology Unit, IRCCS Azienda Ospedaliera Universitaria San Martino-IST Istituto Nazionale per la Ricerca sul Cancro, Genova., Mucciarini C; U.O. Medicina Oncologica, Ospedale Ramazzini, Carpi-AUSL Modena, Carpi., Grillone F; Azienda Ospedaliero-Universitario 'Mater Domini,' Policlinico of Catanzaro, Catanzaro., Mini E; Department of Health Sciences, University of Florence, Firenze., Vignani F; SCDU Oncologia, AO Ordine Mauriziano, Turin., Attademo L; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale,' Napoli, Italy., Pignata S; Department of Urology and Gynecology, Istituto Nazionale Tumori IRCCS Fondazione 'G. Pascale,' Napoli, Italy., Procopio G; Department of Medical Oncology, Fondazione IRCCS Istituto Nazionale dei Tumori, Milan.

المصدر: American journal of clinical oncology [Am J Clin Oncol] 2021 Mar 01; Vol. 44 (3), pp. 121-125.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Lippincott Williams & Wilkins Country of Publication: United States NLM ID: 8207754 Publication Model: Print Cited Medium: Internet ISSN: 1537-453X (Electronic) Linking ISSN: 02773732 NLM ISO Abbreviation: Am J Clin Oncol Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Carcinoma, Renal Cell/*drug therapy , Immune Checkpoint Inhibitors/*therapeutic use , Kidney Neoplasms/*drug therapy, Aged ; Anilides/administration & dosage ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Carcinoma, Renal Cell/mortality ; Carcinoma, Renal Cell/pathology ; Disease Progression ; Everolimus/administration & dosage ; Female ; Humans ; Immune Checkpoint Inhibitors/adverse effects ; Italy ; Kidney Neoplasms/mortality ; Kidney Neoplasms/pathology ; Male ; Middle Aged ; Nivolumab/adverse effects ; Nivolumab/therapeutic use ; Programmed Cell Death 1 Receptor/metabolism ; Pyridines/administration & dosage ; Retrospective Studies ; Treatment Outcome

المؤلفون: Santoleri F; Hospital pharmacist, Pescara General Hospital, Pescara, Italy., Ranucci E; Department Pharmacist, Hematological Oncology Department, Pescara General Hospital, Pescara, Italy., La Barba G; Hematologist, Hematological Oncology Department, Pescara General Hospital, Pescara, Italy., Colasanto I; Hospital pharmacist, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy., Scaldaferri M; Hospital pharmacist, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy., Cattel F; Hospital pharmacist, Azienda Ospedaliero Universitaria Città della Salute e della Scienza di Torino, Torino, Italy., Federici F; Hospital pharmacist, ASUR Marche, Ancona, Italy., Rossi C; Hospital pharmacist, ASUR Marche, Ancona, Italy., Di Biagio K; Environmental Epidemiology Unit - Regional Environmental Protection Agency of Marche, Ancona, Italy., Scortechini AR; Hematologist, Hematology Unit, Azienda Ospedaliero Universitaria Ospedali Riuniti, Ancona, Italy., Musicco F; Hospital Pharmacist at Regina Elena - San Gallicano cancer and dermatological Institute, Rome, Italy., Torquati G; Hospital Pharmacist at Regina Elena - San Gallicano cancer and dermatological Institute, Rome, Italy., Frazzetto A; Hospital Pharmacist at Regina Elena - San Gallicano cancer and dermatological Institute, Rome, Italy., Vozza A; Hospital pharmacist, Azienda Ospedaliera Universitaria 'Federico II', Napoli, Italy., de Rosa C; Hospital pharmacist, Azienda Ospedaliera Universitaria 'Federico II', Napoli, Italy., Lanzillo R; Hospital pharmacist, Azienda Ospedaliera Universitaria 'Federico II', Napoli, Italy., Monteverde M; Biologist, Department of Clinical Medicine and Surgery, Federico II University Medical School, Napoli, Italy., Luciano L; Hematologist, Department of Clinical Medicine and Surgery, Federico II University Medical School, Napoli, Italy., Pane F; Hematologist, Department of Clinical Medicine and Surgery, Federico II University Medical School, Napoli, Italy., Pasquazi A; Hospital pharmacist, Policlinico Tor Vergata PTV Foundation, Roma, Italy., Celeste MG; Hospital pharmacist, Policlinico Tor Vergata PTV Foundation, Roma, Italy., Cantonetti M; Hematologist, Unit of Lymphoproliferative Disorders, Policlinico Tor Vergata PTV Foundation, Roma, Italy., Franceschini L; Hematologist, Unit of Lymphoproliferative Disorders, Policlinico Tor Vergata PTV Foundation, Roma, Italy., Rizzo M; Hematologist, Unit of Lymphoproliferative Disorders, Policlinico Tor Vergata PTV Foundation, Roma, Italy., Costantini A; Hospital pharmacist, Pescara General Hospital, Pescara, Italy.

المصدر: Current medical research and opinion [Curr Med Res Opin] 2021 Mar; Vol. 37 (3), pp. 477-481. Date of Electronic Publication: 2021 Jan 29.

نوع المنشور: Journal Article; Multicenter Study

بيانات الدورية: Publisher: Informa Healthcare Country of Publication: England NLM ID: 0351014 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1473-4877 (Electronic) Linking ISSN: 03007995 NLM ISO Abbreviation: Curr Med Res Opin Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents*/therapeutic use , Leukemia, Myelogenous, Chronic, BCR-ABL Positive*/drug therapy, Dasatinib/therapeutic use ; Humans ; Imatinib Mesylate/therapeutic use ; Italy ; Protein Kinase Inhibitors/therapeutic use ; Pyrimidines ; Thiazoles/therapeutic use ; Treatment Outcome

المؤلفون: Stacchiotti S; Department of Medical Oncology, IRCCS Foundation National Cancer Institute, Milan, Italy., Simeone N; Department of Medical Oncology, IRCCS Foundation National Cancer Institute, Milan, Italy., Lo Vullo S; Unit of Clinical Epidemiology and Trial Organization, IRCCS Foundation National Cancer Institute, Milan, Italy., Baldi GG; Department of Medical Oncology, Santo Stefano Hospital, Prato, Italy., Brunello A; Department of Oncology, Medical Oncology Unit 1, Veneto Institute of Oncology, IRCCS, Padua, Italy., Vincenzi B; Department of Medical Oncology, Biomedical Campus, University of Rome, Rome, Italy., Palassini E; Department of Medical Oncology, IRCCS Foundation National Cancer Institute, Milan, Italy., Dagrada G; Department of Diagnostic Pathology and Laboratory Medicine, IRCCS Foundation National Cancer Institute, Milan, Italy., Collini P; Department of Diagnostic Pathology and Laboratory Medicine, IRCCS Foundation National Cancer Institute, Milan, Italy., Morosi C; Department of Radiology, IRCCS Foundation National Cancer Institute, Milan, Italy., Greco FG; Department of Radiology, IRCCS Foundation National Cancer Institute, Milan, Italy., Sbaraglia M; Department of Pathology, University of Padua Foundation, Padua, Italy., Dei Tos AP; Department of Pathology, University of Padua Foundation, Padua, Italy.; Department of Medicine, University of Padua, Padua, Italy., Mariani L; Unit of Clinical Epidemiology and Trial Organization, IRCCS Foundation National Cancer Institute, Milan, Italy., Frezza AM; Department of Medical Oncology, IRCCS Foundation National Cancer Institute, Milan, Italy., Casali PG; Department of Medical Oncology, IRCCS Foundation National Cancer Institute, Milan, Italy.; Unit of Clinical Epidemiology and Trial Organization, IRCCS Foundation National Cancer Institute, Milan, Italy.; Department of Medical Oncology, Santo Stefano Hospital, Prato, Italy.; Department of Oncology, Medical Oncology Unit 1, Veneto Institute of Oncology, IRCCS, Padua, Italy.; Department of Medical Oncology, Biomedical Campus, University of Rome, Rome, Italy.; Department of Diagnostic Pathology and Laboratory Medicine, IRCCS Foundation National Cancer Institute, Milan, Italy.; Department of Radiology, IRCCS Foundation National Cancer Institute, Milan, Italy.; Department of Pathology, University of Padua Foundation, Padua, Italy.; Department of Medicine, University of Padua, Padua, Italy.; Department of Oncology and Hemato-Oncology, University of Milan, Milan, Italy.

المصدر: Cancer [Cancer] 2021 Feb 15; Vol. 127 (4), pp. 569-576. Date of Electronic Publication: 2020 Oct 27.

نوع المنشور: Journal Article

بيانات الدورية: Publisher: Wiley Country of Publication: United States NLM ID: 0374236 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1097-0142 (Electronic) Linking ISSN: 0008543X NLM ISO Abbreviation: Cancer Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Hemangioendothelioma, Epithelioid/*drug therapy , Intracellular Signaling Peptides and Proteins/*genetics , Sirolimus/*administration & dosage, Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Child ; Disease Progression ; Female ; Hemangioendothelioma, Epithelioid/epidemiology ; Hemangioendothelioma, Epithelioid/genetics ; Hemangioendothelioma, Epithelioid/pathology ; Humans ; Italy/epidemiology ; Kaplan-Meier Estimate ; Male ; Middle Aged ; Prognosis ; Response Evaluation Criteria in Solid Tumors ; Sirolimus/adverse effects ; Transcriptional Coactivator with PDZ-Binding Motif Proteins

المؤلفون: Fazzi R; Hematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Petrini I; General Pathology, Department of Translational Research and New Technologies in Medicine and Surgery, University of Pisa, Pisa, Italy., Giuliani N; Hematology Unit and CTMO, Department of Medicine and Surgery, University of Parma, Parma, Italy., Morganti R; Statistic analysis Unit, Department of Medicine and Oncology, Pisa University Hospital, Pisa, Italy., Carulli G; Hematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Dalla Palma B; Hematology Unit and CTMO, Department of Medicine and Surgery, University of Parma, Parma, Italy., Notarfranchi L; Hematology Unit and CTMO, Department of Medicine and Surgery, University of Parma, Parma, Italy., Galimberti S; Hematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Buda G; Hematology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

المصدر: Frontiers in immunology [Front Immunol] 2021 Feb 03; Vol. 11, pp. 573156. Date of Electronic Publication: 2021 Feb 03 (Print Publication: 2020).

نوع المنشور: Clinical Trial, Phase II; Journal Article; Multicenter Study; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Frontiers Research Foundation] Country of Publication: Switzerland NLM ID: 101560960 Publication Model: eCollection Cited Medium: Internet ISSN: 1664-3224 (Electronic) Linking ISSN: 16643224 NLM ISO Abbreviation: Front Immunol Subsets: MEDLINE

مواضيع طبية MeSH: Bone Marrow Transplantation*/adverse effects, Antineoplastic Combined Chemotherapy Protocols/*therapeutic use , Interleukin-2/*therapeutic use , Multiple Myeloma/*therapy , Zoledronic Acid/*therapeutic use, Adult ; Aged ; Antineoplastic Combined Chemotherapy Protocols/adverse effects ; Chemotherapy, Adjuvant ; Disease Progression ; Female ; Humans ; Interleukin-2/adverse effects ; Italy ; Maintenance Chemotherapy ; Male ; Middle Aged ; Multiple Myeloma/diagnosis ; Remission Induction ; Time Factors ; Treatment Outcome ; Zoledronic Acid/adverse effects

المؤلفون: Giani C; Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Valerio L; Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Bongiovanni A; Osteoncology and Rare Tumors Center Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, IRCCS, Meldola, Italy., Durante C; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy., Grani G; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy., Ibrahim T; Osteoncology and Rare Tumors Center Istituto Scientifico Romagnolo per lo Studio e la Cura dei Tumori IRST, IRCCS, Meldola, Italy., Mariotti S; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy., Massa M; Department of Medical Science, Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy., Pani F; Department of Medical Sciences and Public Health, University of Cagliari, Cagliari, Italy., Pellegriti G; Endocrinology Division, Garibaldy Nesima Hospital, Catania, Italy., Porcelli T; Department of Public Health, University of Naples 'Federico II,' Naples, Italy., Salvatore D; Department of Public Health, University of Naples 'Federico II,' Naples, Italy., Tavarelli M; Endocrinology Division, Garibaldy Nesima Hospital, Catania, Italy., Torlontano M; Department of Medical Science, Fondazione IRCCS Ospedale Casa Sollievo della Sofferenza, San Giovanni Rotondo, Italy., Locati L; Head and Neck Cancer Medical Oncology Unit, Fondazione IRCCS 'Istituto Nazionale dei Tumori,' Milan, Italy., Molinaro E; Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy., Elisei R; Endocrinology Unit, Department of Clinical and Experimental Medicine, University of Pisa, Pisa, Italy.

المصدر: Thyroid : official journal of the American Thyroid Association [Thyroid] 2021 Feb; Vol. 31 (2), pp. 224-232. Date of Electronic Publication: 2020 Oct 22.

نوع المنشور: Journal Article; Multicenter Study; Observational Study

بيانات الدورية: Publisher: Mary Ann Liebert Publishers Country of Publication: United States NLM ID: 9104317 Publication Model: Print-Electronic Cited Medium: Internet ISSN: 1557-9077 (Electronic) Linking ISSN: 10507256 NLM ISO Abbreviation: Thyroid Subsets: MEDLINE

مواضيع طبية MeSH: Health Services Accessibility* , Quality of Life*, Antineoplastic Agents/*therapeutic use , Phenylurea Compounds/*therapeutic use , Protein Kinase Inhibitors/*therapeutic use , Quinolines/*therapeutic use , Thyroid Neoplasms/*drug therapy, Aged ; Aged, 80 and over ; Antineoplastic Agents/adverse effects ; Drug-Related Side Effects and Adverse Reactions/diagnosis ; Drug-Related Side Effects and Adverse Reactions/epidemiology ; Female ; Humans ; Italy/epidemiology ; Male ; Middle Aged ; Phenylurea Compounds/adverse effects ; Prevalence ; Protein Kinase Inhibitors/adverse effects ; Quinolines/adverse effects ; Thyroid Neoplasms/epidemiology ; Thyroid Neoplasms/pathology ; Time Factors ; Treatment Outcome

المؤلفون: Poeschel V; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany. Electronic address: viola.poeschel@uks.eu., Held G; Department of Internal Medicine 1, Westpfalz-Klinikum, Kaiserslautern, Germany. Electronic address: gheld@westpfalz-klinikum.de., Ziepert M; Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany., Witzens-Harig M; Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany., Holte H; Department of Oncology, Oslo University Hospital, Oslo, Norway., Thurner L; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany., Borchmann P; Department of Hematology and Oncology, University Hospital of Cologne, Cologne, Germany., Viardot A; Department of Internal Medicine III, University Hospital Ulm, Ulm, Germany., Soekler M; Department of Internal Medicine II, University Hospital Tuebingen, Tuebingen, Germany., Keller U; Department of Internal Medicine III, Klinikum Rechts der Isar der TU München, Munich, Germany., Schmidt C; Department of Medicine III, University Hospital, Munich, Germany., Truemper L; Department of Hematology and Oncology, Georg August University of Goettingen, Goettingen, Germany., Mahlberg R; Department of Internal Medicine I, Klinikum Mutterhaus der Borromaerinnen, Trier, Germany., Marks R; Department of Hematology and Oncology, University Medical Center, Freiburg, Germany., Hoeffkes HG; Klinikum Fulda Tumorklinik, Fulda, Germany., Metzner B; Department of Hematology and Oncology, Klinikum Oldenburg, Oldenburg, Germany., Dierlamm J; Department of Internal Medicine II, University Hospital Eppendorf, Hamburg, Germany., Frickhofen N; Department of Internal Medicine III, Dr Horst-Schmidt-Kliniken Wiesbaden, Wiesbaden, Germany., Haenel M; Department of Internal Medicine III, Küchwald Hospital Chemnitz, Chemnitz, Germany., Neubauer A; Department of Hematology, Oncology and Immunology, University Hospital Marburg, Marburg, Germany., Kneba M; Department of Internal Medicine II, City Hospital Kiel, Kiel, Germany., Merli F; Hematology Azienda Unità Sanitarie Locali-Istituto di Ricovero e Cura a Carattere Scientifico di Reggio Emilia, Reggio Emilia, Italy., Tucci A; Hematology Azienda Socio Sanitaria Territoriale Spedali Civili Brescia, Brescia, Italy., de Nully Brown P; Department of Hematology, Rigshospitalet, Copenhagen, Denmark., Federico M; Dipartimento Chirurgico, Medico, Odontoiatrico e di Scienze Morfologiche con Interesse Trapiantologico, Oncologico e di Medicina Rigenerativa, University of Modena and Reggio Emilia, Modena, Italy., Lengfelder E; Department of Internal Medicine III, University Hospital Mannheim, Mannheim, Germany., di Rocco A; Department of Translational and Precision Medicine, Sapienza University of Rome, Rome, Italy., Trappe R; Department of Internal Medicine II, Evangelisches Diakonie-Krankenhaus, Bremen, Germany., Rosenwald A; Institute of Pathology, University of Wuerzburg, and Comprehensive Cancer Center Mainfranken, Wuerzburg, Germany., Berdel C; Department of Radiooncology, Saarland University Medical School, Homburg/Saar, Germany., Maisenhoelder M; Department of Oncology, University Hospital of North Norway, Tromsø, Norway., Shpilberg O; Department of Hematology, Rabin Medical Center, Beilinson Hospital, Petah-Tiqwa, Israel., Amam J; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany., Christofyllakis K; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany., Hartmann F; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany., Murawski N; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany., Stilgenbauer S; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany., Nickelsen M; Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg, Germany., Wulf G; Department of Hematology and Oncology, Georg August University of Goettingen, Goettingen, Germany., Glass B; Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg, Germany., Schmitz N; Department of Hematology, Oncology and Stem Cell Transplantation, Asklepios Klinik St Georg, Hamburg, Germany., Altmann B; Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany., Loeffler M; Institute for Medical Informatics, Statistics and Epidemiology, University Leipzig, Leipzig, Germany., Pfreundschuh M; Department of Internal Medicine 1 (Oncology, Hematology, Clinical Immunology, and Rheumatology), Saarland University Medical School, Homburg/Saar, Germany.

مؤلفون مشاركون: FLYER Trial Investigators, German Lymphoma Alliance

المصدر: Lancet (London, England) [Lancet] 2019 Dec 21; Vol. 394 (10216), pp. 2271-2281.

نوع المنشور: Clinical Trial, Phase III; Comparative Study; Equivalence Trial; Journal Article; Multicenter Study; Randomized Controlled Trial; Research Support, Non-U.S. Gov't

بيانات الدورية: Publisher: Elsevier Country of Publication: England NLM ID: 2985213R Publication Model: Print Cited Medium: Internet ISSN: 1474-547X (Electronic) Linking ISSN: 01406736 NLM ISO Abbreviation: Lancet Subsets: MEDLINE

مواضيع طبية MeSH: Antineoplastic Agents, Immunological/*administration & dosage , Antineoplastic Combined Chemotherapy Protocols/*administration & dosage , Lymphoma, Large B-Cell, Diffuse/*drug therapy , Rituximab/*administration & dosage, Administration, Intravenous ; Administration, Oral ; Adult ; Antineoplastic Agents, Immunological/therapeutic use ; Antineoplastic Combined Chemotherapy Protocols/therapeutic use ; Cyclophosphamide/administration & dosage ; Cyclophosphamide/therapeutic use ; Denmark ; Doxorubicin/administration & dosage ; Doxorubicin/therapeutic use ; Drug Administration Schedule ; Female ; Germany ; Humans ; International Cooperation ; Israel ; Italy ; Lymphoma, Large B-Cell, Diffuse/pathology ; Male ; Middle Aged ; Neoplasm Staging ; Norway ; Prednisone/administration & dosage ; Prednisone/therapeutic use ; Prospective Studies ; Rituximab/therapeutic use ; Survival Analysis ; Treatment Outcome ; Vincristine/administration & dosage ; Vincristine/therapeutic use ; Young Adult